4D Molecular Therapeutics Inc.
FDMT | NASDAQ
$15.24
+$0.02 (+0.13%)
At close: Sep 21, 2026, 4:00 PM ET
$15.17
-$0.07 (-0.46%)
After-hours:
Sep 21, 2026, 7:30 PM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 85.21M | 37K | 20.72M | 3.13M | 18.04M | 13.61M |
Cost of Revenue | 7.63M | 141.3M | 97.1M | 80.25M | 61.36M | 53.04M |
Gross Profit | 77.58M | -141.26M | -76.37M | -77.12M | -43.32M | -39.43M |
Operating Income | -159.55M | -187.84M | -112.87M | -110.03M | -71.33M | -56.66M |
Interest Income | 19.48M | 27.05M | 12.21M | 2.57M | 137K | 152K |
Pretax Income | -140.11M | -160.87M | -100.84M | -107.49M | -71.32M | -56.69M |
Net Income | -140.11M | -160.87M | -100.84M | -107.49M | -71.32M | -56.69M |
Selling & General & Admin | 49.06M | 46.58M | 36.49M | 32.91M | 28.01M | 17.24M |
Research & Development | 195.7M | 141.3M | 97.1M | 80.25M | 61.36M | 53.04M |
Other Expenses | -7.63M | -141.3M | -97.1M | -80.25M | -61.36M | -53.04M |
Operating Expenses | 237.13M | 46.58M | 36.49M | 32.91M | 28.01M | 17.24M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 244.76M | 187.88M | 133.59M | 113.16M | 89.37M | 70.28M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 57.93M | 53.94M | 39.13M | 32.35M | 27.73M | 26.68M |
Shares Outstanding (Diluted) | 57.93M | 53.94M | 39.13M | 32.35M | 27.73M | 26.68M |
EPS (Basic) | -2.42 | -2.98 | -2.58 | -3.12 | -2.46 | -2.12 |
EPS (Diluted) | -2.42 | -2.98 | -2.58 | -3.12 | -2.46 | -2.12 |
EBITDA | -132.48M | -154.16M | -96.63M | -105.09M | -69.79M | -55.22M |
EBIT | -140.11M | -160.87M | -100.84M | -107.49M | -71.32M | -56.66M |
Depreciation & Amortization | 7.63M | 6.71M | 4.2M | 2.4M | 1.52M | 1.44M |
Add to Watchlist
Select watchlists to add or remove FDMT